DIA421.42-2.43 -0.57%
SPX5,888.55-32.99 -0.56%
IXIC19,100.94-98.23 -0.51%

Based on the provided financial report articles, I generated the title for the article: "Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, of Company 0000883107" Please note that the title may not be exact, as the provided text appears to be a financial report in XML format, and the title may not be explicitly stated.

Press release·04/05/2025 05:40:14
Listen to the news
Based on the provided financial report articles, I generated the title for the article: "Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, of Company 0000883107" Please note that the title may not be exact, as the provided text appears to be a financial report in XML format, and the title may not be explicitly stated.

Based on the provided financial report articles, I generated the title for the article: "Annual Report (Form 10-K) for the fiscal year ended December 31, 2024, of Company 0000883107" Please note that the title may not be exact, as the provided text appears to be a financial report in XML format, and the title may not be explicitly stated.

The financial report presents the financial statements of the company for the fiscal year ended December 31, 2024, as well as the comparative financial statements for the fiscal year ended December 31, 2023. The company reported total revenues of $X, with net income of $Y. The company’s balance sheet as of December 31, 2024, shows total assets of $Z, total liabilities of $W, and total equity of $V. The company’s cash flow statement shows net cash provided by operating activities of $X, net cash used in investing activities of $Y, and net cash provided by financing activities of $Z. The company’s financial position and results of operations are presented in the financial statements, which are accompanied by notes and schedules that provide additional information about the company’s financial performance and position.

Overview

Solésence is a health-oriented, science-driven company focused on various skin health and beauty markets. The company’s primary products are fully developed prestige skin care formulations with mineral-based UV protection enabled by their proprietary Active Pharmaceutical Ingredients (APIs). These APIs are also marketed for sale to manufacturers of other skin health products, including sunscreens and daily care products. Solésence also continues to sell products in legacy markets such as medical diagnostics, architectural coatings, industrial coating applications, abrasion-resistant additives, and plastics additives applications.

Critical Accounting Estimates

Solésence monitors the value of its inventory for the effects of aging, obsolescence, and seasonality. The company adjusts inventory valuation when management determines there is potential for obsolete materials. In 2024, Solésence applied a $1,987,000 inventory reserve in anticipation of some materials nearing expiration, becoming obsolete, or no longer being used regularly.

Certain assumptions are necessary to assess the impact of risks and uncertainties on Solésence’s financial information, such as cash flow projections, availability of capital, and expected compliance with contractual commitments. While costs have continued to increase on an inflationary basis, the company believes it will be able to offset much of this cost through greater production efficiencies and increased pricing.

Results of Operations

Years Ended December 31, 2024 and 2023

Total revenue increased to $52,347,000 in 2024, compared to $37,297,000 in 2023. This was primarily due to an increase in revenue from Solésence’s consumer products, partially offset by decreased personal care ingredients and advanced materials products.

Current Significant Customers

Customer # Product Category 2024 2023
1 Consumer Products 32% 17%
2 Personal Care Ingredients 13% 25%
3 Consumer Products 7% 15%
Total 52% 57%

Cost of revenue increased to $36,159,000 in 2024, compared to $29,472,000 in 2023, primarily driven by higher materials and direct labor costs related to the increased sales volume. Solésence expects to continue new materials development and dispersion technologies for personal care applications and its formulated Solésence products during 2025 and beyond.

Research and development expense remained the same in 2024 at $3,837,000, with higher labor costs offset by lower legal and consulting costs. Solésence expects research and development expenses to increase slightly in 2025 depending on growth in its Solésence line of products and related technologies.

Selling, general and administrative expense decreased to $7,219,000 in 2024, compared to $7,534,000 in 2023, largely due to a decrease in legal costs. Solésence expects 2025 expenses in this area to be slightly higher due to expanding parts of its administrative functions.

Interest expense decreased to $670,000 in 2024, compared to $838,000 in 2023, due to lower interest rates and decreased usage of debt facilities.

Solésence believes inflation has not had a material effect on its operations or financial position for 2024, but expects supplier price increases and wage and benefit inflation may have a material effect on its operations and financial position in 2025 and beyond.

Liquidity and Capital Resources

Cash provided by operating activities increased by $3,977,000 in 2024 compared to 2023, mainly due to the company earning $4,235,000 in net income in 2024 compared to a $4,390,000 net loss in 2023. Cash capital expenditures amounted to approximately $4,558,000 and $1,051,000 for the years ended December 31, 2024 and 2023, respectively.

Solésence has a credit agreement with Libertyville to support its obligations under its leased manufacturing and warehouse space, with no outstanding borrowings as of December 31, 2024. The company also has various loan agreements with related parties to support its working capital needs, including an asset-based revolving loan facility, an inventory facility, and a term loan.

On March 1, 2024, Solésence entered into a Securities Purchase Agreement with Strandler, LLC, an affiliate of the company’s controlling shareholder, to issue 15,000 shares of Series X Preferred Stock for $6,000,000. The preferred stock is convertible into common stock, subject to certain conditions.

Solésence’s future capital requirements will depend on many factors, including customer acceptance of its products, progress in research and development, and the costs necessary to increase and expand its manufacturing capabilities. The company expects capital spending relating to currently known capital needs for 2025 to be between $6 million and $8 million, to be funded by profit from operations, existing loans and lines of credit, and possible new financing.

Solésence has federal and Illinois net operating loss carryforwards that may be subject to certain limitations, and the company has concluded that it is likely some portion of these carryforwards will expire before ultimately becoming available to reduce income tax liabilities.

Risk Disclosure: The content of this page is not an investment advice and does not constitute any offer or solicitation to offer or recommendation of any investment product. It is for general purposes only and does not take into account your individual needs, investment objectives and specific financial circumstances. All investments involve risk and the past performance of securities, or financial products does not guarantee future results or returns. Keep in mind that while diversification may help spread risk it does not assure a profit, or protect against loss, in a down market. There is always the potential of losing money when you invest in securities, or other financial products. Investors should consider their investment objectives and risks carefully before investing. For more details, please refer to risk disclosure.
During the campaign period, US stocks, US stocks short selling, US stock options, Hong Kong stocks, and A-shares trading will maintain at $0 commission, and no subscription/redemption fees for mutual fund transactions. $0 fee offer has a time limit, until further notice. For more information, please visit:  https://www.webull.hk/pricing
Webull Securities Limited is licensed with the Securities and Futures Commission of Hong Kong (CE No. BNG700) for carrying out Type 1 License for Dealing in Securities, Type 2 License for Dealing in Futures Contracts and Type 4 License for Advising on Securities.
Language

English

©2025 Webull Securities Limited. All rights reserved.